We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Dyslipidemia in Type 2 Diabetes (0767-034)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00547274
Recruitment Status : Terminated
First Posted : October 22, 2007
Last Update Posted : June 12, 2015
Information provided by (Responsible Party):

October 19, 2007
October 22, 2007
June 12, 2015
July 2003
November 2003   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00547274 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Dyslipidemia in Type 2 Diabetes (0767-034)
Not Provided

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Diabetes Mellitus, Type II
  • Dyslipidemia
Drug: MK0767
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2003
November 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and non-pregnant females
  • Age greater than or equal to 21 years
  • Stop current diabetes therapy (if applicable)
  • Stop current statin therapy (if applicable)

Exclusion Criteria:

  • History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
  • Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
  • Patients requiring treatment with corticosteroids for more than 14 consecutive days
  • Patients taking warfarin or warfarin-like anti-coagulants
  • Patients undergoing surgery within 30 days of Visit 1
  • Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
  • Patients with history of pancreatitis or uncontrolled high blood pressure
Sexes Eligible for Study: All
21 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP